The authors reply

New England Journal of Medicine

Volumn 376, Issue 24, 2017, Pages 2402-

  Pinsky, Paul F ^a   Prorok, Philip C ^a   Kramer, Barnett J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; DIAGNOSTIC ERROR; HORMONAL THERAPY; HUMAN; LETTER; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; EARLY CANCER DIAGNOSIS; MALE; MASS SCREENING; PROSTATE TUMOR;

EARLY DETECTION OF CANCER; HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 85020497506     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1705480     Document Type: Letter

References (5)

1. Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer. II. Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 1999; 91: 1025-32.
2. Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 2014; 120: 818-23.
3. Schröder FH, Hugosson J, Carlsson S, et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2012; 62: 745-52.
4. Shelley MD, Kumar S, Coles B, Wilt T, Staffurth J, Mason MD. Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: A systematic review and meta-analysis of randomised trials. Cancer Treat Rev 2009; 35: 540-6.
5. Etzioni R, Gulati R, Tsodikov A, et al. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer 2012; 118: 5955-63.